Background —The study of QT dispersion (QTd) is of increasing clinical interest, but there are very few data in large healthy populations. Furthermore, there is still discussion on the extent to which QTd reflects dispersion of measurement. This study addresses these problems. Methods and Results —Twelve-lead ECGs recorded on 1501 apparently healthy adults and 1784 healthy neonates, infants, and children were used to derive normal limits of QTd and QT intervals by use of a fully automated approach. No age gradient or sex differences in QTd were seen and it was found that an upper limit of 50 ms was highly specific. Three-orthogonal-lead ECGs (n=1220) from the Common Standards for Quantitative Electrocardiography database were used to generate derived 12-lead ECGs, which had a significant increase in QTd of 10.1±13.1 ms compared with the original orthogonal-lead ECG but a mean difference of only 1.63±12.2 ms compared with the original 12-lead ECGs. In a population of 361 patients with old myocardial infarction, there was a statistically significant increase in mean QTd compared with that of the adult normal group (32.7±10.0 versus 24.53±8.2 ms; P <0.0001). An estimate of computer measurement error was also obtained by creating 2 sets of 1220 ECGs from the original set of 1220. The mean error (difference in QTd on a paired basis) was found to be 0.28±9.7 ms. Conclusions —These data indicate that QTd is age and sex independent, has a highly specific upper normal limit of 50 ms, is significantly lower in the 3-orthogonal-lead than in the 12-lead ECG, and is longer in patients with a previous myocardial infarction than in normal subjects.
Objectives-To review the New Zealand coronary artery bypass priority score instituted in May 1996, and specifically to determine whether it prioritises patients at high risk of cardiac events while waiting. The New Zealand score is compared with the Ontario urgency rating score, and waiting times for surgery are compared with the maximum times recommended by the Ontario consensus panel. Design-Retrospective review of patients accepted for isolated coronary artery bypass surgery between 1 January 1993 and 31 January 1996. Setting-Green Lane Hospital, Auckland, New Zealand. Main outcome measures-Waiting time, cardiac death, myocardial infarction, and cardiac readmission. Results-The median waiting times were five days for hospital cases (n = 721) and 146 days for out of hospital cases (n = 701). Of the latter group, 28% waited more than a year, 33% had their surgery expedited because of worsening symptoms, and 19% failed to meet the cut oV point set by the New Zealand score for acceptance onto the list. Twenty two patients died, 18 on the outpatient waiting list (waiting list mortality 2.6%, risk 0.28% per month of waiting), and 132 were readmitted, 12% with myocardial infarction and 76% with unstable angina. Risk factors for a composite end point of death or myocardial infarction and/or cardiac readmission were: previous coronary artery bypass surgery (p = 0.001), class III or IV angina (p = 0.002), and hypertension (p = 0.005). The New Zealand score did not identify those at risk. Excluding hospital cases, 32% had surgery within the time recommended by the Ontario consensus panel. Conclusions-Waiting times for coronary artery bypass surgery in New Zealand are considerably longer than those in Ontario, Canada. By using a numerical cut oV point, implementation of the New Zealand priority scoring system has restricted access to coronary surgery on the basis of funding constraints rather than clinical appropriateness. The score does not add greatly to the clinicians' prioritisation in predicting those patients who will suVer events while waiting. (Heart 1999;81:586-592)
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.